Clinical trials: Duloxetine
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Urinary Stress Incontinence
Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence
Biomechanical and electrophysiological effects of duloxetine in the treatment of women with urinary stress incontinence
- Trial name
- NCT00190853
- Testing
- Duloxetine
- Where
- 19 sites in United States, Slovenia and 1 more
- Volunteers
- 93 people
- Sponsor
- Eli Lilly and Company
Healthy
Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition
This study were to compare the relative bioavailability of Duloxetine HCl delayed release capsule 60 mg with that of 'CYMBALTA®' delayed release capsule 60 mg (Duloxetine HCl delayed release capsule 60 mg) in healthy, adult…
- Trial name
- NCT02291367
- Testing
- Duloxetine, Cymbalta®
- Where
- India
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Urinary Stress Incontinence
Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence
Double-blind placebo-controlled study of the biomechanical effects of duloxetine compared with placebo in the treatment of women with pure genuine stress incontinence
- Trial name
- NCT00190567
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Depression
Duloxetine vs. Active Comparator for the Treatment of Depression
How duloxetine compares to a medication currently available for the treatment of depression in the treatment of patients with major depressive disorder.
- Trial name
- NCT00067912
- Testing
- Duloxetine Hydrochloride, Venlafaxine Extended Release
- Where
- Canada
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
- Trial name
- NCT00105989
- Testing
- Duloxetine
- Where
- 34 sites in United States, France and 4 more
- Volunteers
- 514 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathies
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
To determine if duloxetine 60 mg once daily can work up to 6 months in treating pain from Diabetic Neuropathy.
- Trial name
- NCT00322621
- Testing
- Duloxetine
- Where
- 19 sites in Brazil, France and 2 more
- Volunteers
- 216 people
- Sponsor
- Eli Lilly and Company
Fibromyalgia
An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)
The purpose of the study is to assess the safety and efficacy of duloxetine in participants with fibromyalgia at long-term use.
- Trial name
- NCT01621191
- Testing
- Duloxetine
- Where
- Japan
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder
Duloxetine for the Treatment of Generalized Anxiety Disorder
This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder
- Trial name
- NCT00803361
- Testing
- Duloxetine
- Where
- 7 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Urinary Incontinence Stress
Open Label Phase III Duloxetine Study for Stress Urinary Incontinence
The purpose of this study is to monitor the long term safety of duloxetine in the treatment of stress urinary incontinence.
- Trial name
- NCT00191204
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 363 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate the efficacy, tolerability and the safety of two fixed doses of vortioxetine in the treatment of major depressive disorder.
- Trial name
- NCT01140906
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 607 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain
The purpose of this study was to investigate the efficacy of duloxetine versus placebo on pain in outpatients with major depressive disorder (MDD): change in Brief Pain Inventory Short Form (BPI-SF) 24-hour average pain score…
- Trial name
- NCT02232555
- Testing
- Duloxetine
- Volunteers
- 327 people
- Sponsor
- Boehringer Ingelheim
Anxiety Disorders
Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
This is a clinical trial assessing the time to relapse of anxiety symptoms among patients with generalized anxiety disorder who have responded to duloxetine therapy.
- Trial name
- NCT00122863
- Testing
- Duloxetine Hydrochloride
- Where
- 47 sites in United States, Austria and 5 more
- Volunteers
- 380 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.
- Trial name
- NCT00529789
- Testing
- duloxetine
- Where
- 22 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
Study to assess efficacy of Duloxetine 120 mg and Duloxetine 60 mg in patients hospitalized for severe depression after 4 weeks of treatment. To evaluate the rescue option in non-responding patients.
- Trial name
- NCT02229825
- Testing
- Duloxetine
- Volunteers
- 339 people
- Sponsor
- Boehringer Ingelheim
Fibromyalgia
A Study of Duloxetine in the Treatment of Fibromyalgia
This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.
- Trial name
- NCT00125892
- Testing
- duloxetine
- Where
- 27 sites in Argentina, Australia and 5 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
Duloxetine in the Treatment of Melancholic Depression
The purpose of this study is to determine the optimal treatment strategy for MDD patients with melancholic features who do not respond to a standard daily dose.
- Trial name
- NCT00191685
- Testing
- duloxetine
- Where
- 23 sites in Australia, Canada
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder
Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder
The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.
- Trial name
- NCT00036309
- Testing
- Duloxetine Hydrochloride
- Where
- United States
- Sponsor
- Eli Lilly and Company
Fibromyalgia
A Study of Duloxetine in Fibromyalgia
The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.
- Trial name
- NCT01552057
- Testing
- Duloxetine 60 mg
- Where
- Japan
- Volunteers
- 393 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of Patients With Major Depressive Disorder and Residual Apathy
The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a…
- Trial name
- NCT00985504
- Testing
- Duloxetine, Escitalopram
- Where
- 15 sites in Australia, Canada and 3 more
- Volunteers
- 483 people
- Sponsor
- Eli Lilly and Company